Kezar Life Sciences (NASDAQ:KZR) Trading 3.1% Higher

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) were up 3.1% on Tuesday . The stock traded as high as $0.85 and last traded at $0.84. Approximately 452,675 shares changed hands during trading, a decline of 34% from the average daily volume of 681,233 shares. The stock had previously closed at $0.81.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Kezar Life Sciences in a report on Friday, March 15th.

Kezar Life Sciences Stock Up 3.1 %

The firm has a market capitalization of $61.15 million, a PE ratio of -0.60 and a beta of 0.47. The company has a current ratio of 11.66, a quick ratio of 11.66 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average of $0.88 and a two-hundred day moving average of $0.87.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, equities research analysts forecast that Kezar Life Sciences, Inc. will post -1.26 EPS for the current year.

Institutional Investors Weigh In On Kezar Life Sciences

Several institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC grew its stake in shares of Kezar Life Sciences by 33.8% in the fourth quarter. SG Americas Securities LLC now owns 43,950 shares of the company’s stock valued at $42,000 after buying an additional 11,109 shares in the last quarter. Fidelis Capital Partners LLC acquired a new stake in Kezar Life Sciences in the first quarter valued at approximately $25,000. Pale Fire Capital SE acquired a new stake in Kezar Life Sciences in the third quarter valued at approximately $82,000. BNP Paribas Financial Markets lifted its position in shares of Kezar Life Sciences by 35.4% during the first quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after purchasing an additional 71,543 shares in the last quarter. Finally, Panagora Asset Management Inc. purchased a new position in shares of Kezar Life Sciences in the fourth quarter valued at $80,000. 67.90% of the stock is currently owned by hedge funds and other institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.